ASOGI24 1日目 注目演題まとめ
Day 1 #GI24 @ASCO Highlights #CommunityOncology
— Oncology Brothers (@OncBrothers) January 19, 2024
1. #KN590 update
2. #Docetaxel + FOLFOX in 1L GEJ/gastric AdenoCa
3. PeriOp IO in:
- GEJ/Gastric (#MATTERHORN)
- LA-ESCC (#ESCORTNEO)
4. #SKYSCRAPER08 (anti-TIGIT) in mESCC#OncEd #MedEd #OncTwitter #MedTwitter #gism
1/6 pic.twitter.com/Za3GfUfp6w
‘Oncology Brothers‘ 一日目のハイライト
1:Keynote590 長期データ
試験は↓ 参考
https://twitter.com/SuyogCancer/status/1748039172475257277
5 year update keynote 590. Pembrolizumab plus chemo continues to do better than chemo alone for advanced eso cancer. Look at the curves . They are getting plateue. Probably we have long term responders. Benifit more with CPS > 10 and squamous histology @asco #GI24.… pic.twitter.com/721H4kL4RX
— Dr Amol Akhade (@SuyogCancer) January 18, 2024
一応5年の時点で見てもtailはありそうです
(肺がんやメラノーマに比べると… ですが)
2:胃がん・胃接合部がんにFOLOFOX/CAPOXに
ドセタキセルの上乗せはどうか?
→上乗せ示せず…
2. Addition of #Docetaxel to SoC at the time (FOLFOX/CapOX) in 1L m Gastric/GEJ adenocarcinoma:
— Oncology Brothers (@OncBrothers) January 19, 2024
- Associated with higher toxicities
- Did not meet its primary endpoint
- FOLFOX/CapOX with IO remains current SoC (@YJanjigianMD shared bio marker driven strategies)
3/6 https://t.co/gdJaun65KK pic.twitter.com/T0WyDP0hxl
3:術前IO
MATTERHORN試験
胃がん・胃接合部がんで FLOTにデュルバルマブ上乗せ
pCR率は上昇。OSはまだ何とも言えない、という書きっぷり
ESCORTNEO試験
3b. PeriOp IO in locally advanced esophageal squam cell Ca: #Camrelizumab + Chemo, Ph III:
— Oncology Brothers (@OncBrothers) January 19, 2024
- Improved pCR (28% in Cam/Nab-Pac/Cis arm vs 15.4% in Cam/Pac/Cis arm vs 4.7% in Cis/Pac arm)
- Pending EFS (but trend towards positive EFS)
- Mature data likely to change SoC
5/6 https://t.co/68XYounfkV pic.twitter.com/LXwMEp3BFj
進行食道扁平上皮がんにケモ+カムレリツマブ(T4は入っていない)
pCR 率改善(ケモはNab-PTXorPTX+CDDPやカルパク)
OSもこちらも何とも言えないと。
Cam/Nab-Pac/CisのpCR率が28%と結構高い。
4:TGIT抗体が、食道がんで上乗せ!
4. #SKYSCRAPER08: 1L #Tiragolumab (anti-TIGIT) + Atezo + Cis/Pac in met esophageal squam cell cancer, Ph III
— Oncology Brothers (@OncBrothers) January 19, 2024
- 1st anti-TIGIT to show +ve data in Ph III ESCC
- mOS ⬆️ by 4mos (15.7mos vs 11.1mos), HR 0.70
- Asian population (study done in China)
- New SoC if approved
6/6 https://t.co/2WA9WBmWPD pic.twitter.com/yISnfMr9y9
III相試験でコケまくっていたTGIT抗体(チラゴルマブ)が成功!
アテゾ‐シス‐パクリ‐チラゴルマブ
HR0.7と結構いい差。しかも中国の試験で日本でも期待できる。
アテゾの効果でないことを祈るのみ…
(ただ、1のKeynoteよりはいい感じなので、期待。)
この記事が気に入ったらサポートをしてみませんか?